Cargando…

Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study

BACKGROUND: Anti‐angiogenic therapy with bevacizumab (BEV), an anti‐VEGF antibody, plays a critical role in the treatment of ovarian cancer. However, despite an encouraging initial response, most tumors become resistant to BEV over time, and a new strategy that enables sustainable treatment using BE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Tianyue, Mitamura, Takashi, Wang, Lei, Kubota, Shimpei I., Murakami, Masaaki, Tanaka, Shinya, Watari, Hidemichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166889/ https://www.ncbi.nlm.nih.gov/pubmed/36810973 http://dx.doi.org/10.1002/cam4.5674

Ejemplares similares

Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer
por: Mitamura, Takashi, et al.
Publicado: (2022)

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel
por: Hassan, Mohamed K, et al.
Publicado: (2011)

P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane
por: Hassan, Mohamed Kamel, et al.
Publicado: (2015)

Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
por: Ueda, Akihiko, et al.
Publicado: (2022)

microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway
por: Mitamura, Takashi, et al.
Publicado: (2014)

miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2
por: Mohamed, Zeinab, et al.
Publicado: (2018)

Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments
por: Mitamura, Takashi, et al.
Publicado: (2014)

Oncological Outcomes After Okabayashi-Kobayashi Radical Hysterectomy for Early and Locally Advanced Cervical Cancer
por: Sakuragi, Noriaki, et al.
Publicado: (2020)

Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer
por: Miao, Yu, et al.
Publicado: (2023)

The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study
por: Mitamura, Takashi, et al.
Publicado: (2021)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Correction: microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway
por: Mitamura, Takashi, et al.
Publicado: (2014)

Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results
por: Mitamura, Yoshinori, et al.
Publicado: (2010)

Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy
por: Kato, Tatsuya, et al.
Publicado: (2013)

Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
por: Tanaka, Yuji, et al.
Publicado: (2018)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
por: Kitahashi, Masayasu, et al.
Publicado: (2014)

Nerve-sparing radical hysterectomy in the precision surgery for cervical cancer
por: Sakuragi, Noriaki, et al.
Publicado: (2020)

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Multivariate survival analysis of the patients with recurrent endometrial cancer
por: Odagiri, Tetsuji, et al.
Publicado: (2011)

Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
por: Nonaka, Michiko, et al.
Publicado: (2018)

Frequency of night shift and menstrual cycle characteristics in Japanese nurses working under two or three rotating shifts
por: Mayama, Michinori, et al.
Publicado: (2020)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells
por: Abd-Rabou, Ahmed A, et al.
Publicado: (2019)

Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups
por: Todo, Yukiharu, et al.
Publicado: (2016)

In vivo optical cellular diagnosis for uterine cervical or vaginal intraepithelial neoplasia using flexible gastrointestinal endocytoscopy -a prospective pilot study-
por: Ono, Shoko, et al.
Publicado: (2020)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo
por: Li, Wei, et al.
Publicado: (2011)

MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells
por: Konno, Yosuke, et al.
Publicado: (2014)

Adjuvant chemotherapy for early-stage cervical cancer
por: Asano, Hiroshi, et al.
Publicado: (2016)

Chemotherapy and molecular targeting therapy for recurrent cervical cancer
por: Tsuda, Naotake, et al.
Publicado: (2016)

Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET
por: Mitamura, T, et al.
Publicado: (2013)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2015)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
por: Wang, Yingwen, et al.
Publicado: (2023)

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
por: Hettle, Robert, et al.
Publicado: (2021)

Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
por: Wu, Yutuan, et al.
Publicado: (2022)

CCR5 Inhibitors and HIV-1 Infection
por: Latinovic, Olga S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g9bfab20gaal0gqoi3mlnq5krj